No-Spa (Drotaverine Hydrochloride)

Drotaverine hydrochloride works by inhibiting phosphodiesterase enzymes, which raises intracellular cyclic AMP levels. The increased cAMP leads to reduced calcium entry into smooth‑muscle cells, causing relaxation of the muscle fibers and decreasing spasm. This mechanism also provides a mild calcium‑antagonist effect, contributing to its antispasmodic action.

The appropriate dose of No‑Spa is determined by a qualified prescriber based on the patient’s condition, age, weight and overall health. Healthcare professionals tailor the regimen to achieve optimal symptom control while minimizing potential adverse effects.

Safety data for drotaverine hydrochloride in pregnancy are limited, so it should only be used if the potential benefit justifies the risk and after consulting a healthcare provider. During breastfeeding, caution is advised because the extent of drug excretion in breast milk is not well established.

To order No‑Spa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other antispasmodics such as hyoscine or papaverine, drotaverine offers a phosphodiesterase‑inhibiting mechanism rather than anticholinergic activity, resulting in fewer anticholinergic side effects like dry mouth or blurred vision. Its calcium‑antagonist effect also provides a broader smooth‑muscle relaxation profile.

No‑Spa tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect the product from moisture, direct sunlight and extreme heat to maintain stability and potency throughout its shelf life.

No‑Spa is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably after a meal to reduce gastrointestinal irritation, unless otherwise directed by a healthcare professional.

Serious risks, although rare, include severe allergic reactions such as anaphylaxis, marked hypotension leading to dizziness or fainting, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms like rash, swelling, rapid heartbeat, or a sudden drop in blood pressure.

No‑Spa should be avoided in individuals with known hypersensitivity to drotaverine or any tablet excipients. Caution is also advised for patients with severe cardiovascular disease, uncontrolled hypertension, or those taking medications that may cause additive hypotensive effects, unless a prescriber decides otherwise.